Novel seizure outcomes in patients with Lennox‐Gastaut syndrome: Post hoc analysis of seizure‐free days in rufinamide Study 303

Novel seizure outcomes in patients with Lennox‐Gastaut syndrome: Post hoc analysis of seizure‐free days in rufinamide Study 303

Summary Objective Drug development for patients with Lennox‐Gastaut syndrome (LGS) is based on clinical trials that use drop seizure counts. However, such counts do not assess total seizure burden and affect a patient's quality of life (QoL). In this post hoc analysis, we evaluated two novel se...

Full description

Bibliographic Details
Main Authors: Stéphane Auvin, Betsy Williams, Rob McMurray, Dinesh Kumar, Carlos Perdomo, Manoj Malhotra
Format: Article
Language:English
Published: Wiley 2019-06-01
Series:Epilepsia Open
Subjects:
antiseizure drug
children
epilepsy
Lennox‐Gastaut syndrome
rufinamide
Online Access:https://doi.org/10.1002/epi4.12314

Internet

https://doi.org/10.1002/epi4.12314

Similar Items